SCHEMBL276255

SCHEMBL276255

Oc1scc2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.42
PTPN22 Q9Y2R2 1/20 0.39
TRPM4 Q8TD43 1/20 0.39
CYP2A6 P11509 4/20 0.39
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 2/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NQO2 P16083 1/20 0.38
IDO1 P14902 1/20 0.38
POLB P06746 1/20 0.37
HPRT1 P00492 1/20 0.36
USP2 O75604 1/20 0.35
PAK1 Q13153 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
CNR2 P34972 1/20 0.35
MAPT P10636 1/20 0.34
ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7209479 0.75 CNR2 (0.40) CYP1A2CYP2A6ALDH1A1HSD17B10TSHR
SCHEMBL13261664 0.74 ALDH1A1 (0.43) CYP1A2CYP2A6ALDH1A1HSD17B10TSHR
SCHEMBL17394560 0.73 ALDH1A1 (0.38) CYP1A2CYP2A6ALDH1A1HSD17B10TSHR
SCHEMBL1097973 0.72 CYP2A6 (0.41) CYP1A2CYP2A6ALDH1A1HSD17B10TSHR
SCHEMBL2008188 0.72 CYP2A6 (0.41) CYP1A2CYP2A6ALDH1A1HSD17B10TSHR
SCHEMBL10605324 0.71 HSD17B10 (0.38) CYP1A2PTPN22TRPM4CYP2A6ALDH1A1
SCHEMBL2008190 0.70 ALDH1A1 (0.42) CYP2A6ALDH1A1HSD17B10TSHRTDP1
SCHEMBL21177767 0.70 CYP2A6 (0.39) CYP1A2CYP2A6ALDH1A1HSD17B10TSHR
SCHEMBL276253 0.70 ALDH1A1 (0.39) CYP1A2CYP2A6ALDH1A1HSD17B10TSHR
SCHEMBL3149291 0.70 ALDH1A1 (0.42) CYP1A2CYP2A6ALDH1A1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190221750-A1 CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2019-07-18 US claimed
US-20190185457-A1 HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND SAMSUNG ELECTRONICS CO LTD (KR) 2019-06-20 US claimed
US-5594020-A FUNGICIDE BASF AKTIENGESELLSCHAFT (DE) 1997-01-14 US claimed
US-11997917-B2 Quantum dot electroluminescence device SAMSUNG ELECTRONICS CO., LTD. (KR) 2024-05-28 US disclosed
EP-3674290-B1 HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND SAMSUNG ELECTRONICS CO LTD (KR) 2024-05-22 EP disclosed
US-20240114765-A1 QUANTUM DOT ELECTROLUMINESCENCE DEVICE SAMSUNG ELECTRONICS CO LTD (KR) 2024-04-04 US disclosed
US-11925106-B2 Condensed cyclic compound, composition including the same, and organic light-emitting device including the condensed cyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2024-03-05 US disclosed
US-11706977-B2 Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-07-18 US disclosed
US-11697645-B2 Heterocyclic compound, composition including heterocyclic compound, and organic light-emitting device including heterocyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-07-11 US disclosed
US-20230140682-A1 Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound SAMSUNG ELECTRONICS CO LTD (KR) 2023-05-04 US disclosed
EP-4174054-A1 HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND Samsung Electronics Co., Ltd. (KR) 2023-05-03 EP disclosed
EP-1816152-A1 POLYMERIZABLE COMPOSITION TOYO INK MFG. CO., LTD. (JP) 2007-08-08 EP disclosed
CN-1798739-A 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators NISSAN CHEMICAL IND LTD (JP) 2006-07-05 CN disclosed
WO-2006062240-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-15 WO disclosed
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2006-05-04 US disclosed
EP-1636192-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2006-03-22 EP disclosed
WO-2004108683-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2004-12-16 WO disclosed
US-5719171-A INSECTICIDES; MITICIDES; NEMATOCIDES; FUNGICIDES BASF AKTIENGESELLSCHAFT (DE) 1998-02-17 US disclosed
US-5594020-A FUNGICIDE BASF AKTIENGESELLSCHAFT (DE) 1997-01-14 US disclosed
EP-0621277-A2 Diarylderivatives and their use for the protection of plants BASF Aktiengesellschaft (DE) 1994-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11697645-B2 Heterocyclic compound, composition including heterocyclic compound, and organic light-emitting device including heterocyclic compound CYP1B1, CYP1A1, CCNT1 CYP1A2 111/4885PTPN22 4727/4885TRPM4 925/4885
US-11706977-B2 Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound CRY1, CYP1B1, CYP1A1 CYP1A2 19/4885PTPN22 4582/4885TRPM4 847/4885
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NR2C2, ROR1, NR0B2 CYP1A2 434/4885PTPN22 607/4885TRPM4 578/4885
US-20230140682-A1 Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound CCNT1, CCNA1, CYP1B1 CYP1A2 64/4885PTPN22 4626/4885TRPM4 1630/4885
US-11925106-B2 Condensed cyclic compound, composition including the same, and organic light-emitting device including the condensed cyclic compound CCNB1, CCNA1, CCNT1 CYP1A2 712/4885PTPN22 4624/4885TRPM4 1155/4885
US-20190185457-A1 HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND CRY1, NAP1L1, CYP1A1 CYP1A2 35/4885PTPN22 4218/4885TRPM4 1772/4885
US-20190221750-A1 CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND CRY1, CRY2, MCM4 CYP1A2 1494/4885PTPN22 4676/4885TRPM4 1145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.